Tyme Technologies Inc (NASDAQ:TYME) CEO Steve Hoffman sold 51,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $1.21, for a total transaction of $61,710.00. Following the completion of the transaction, the chief executive officer now directly owns 26,390,449 shares of the company’s stock, valued at $31,932,443.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Steve Hoffman also recently made the following trade(s):
- On Thursday, July 16th, Steve Hoffman sold 51,299 shares of Tyme Technologies stock. The stock was sold at an average price of $1.26, for a total transaction of $64,636.74.
NASDAQ:TYME opened at $1.19 on Friday. The company’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.33. Tyme Technologies Inc has a 52 week low of $0.86 and a 52 week high of $2.04. The stock has a market cap of $150.67 million, a price-to-earnings ratio of -6.61 and a beta of 0.97.
Tyme Technologies (NASDAQ:TYME) last issued its earnings results on Wednesday, May 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.03. On average, sell-side analysts forecast that Tyme Technologies Inc will post -0.28 EPS for the current year.
Hedge funds have recently modified their holdings of the stock. Nuveen Asset Management LLC boosted its holdings in Tyme Technologies by 17.8% in the first quarter. Nuveen Asset Management LLC now owns 250,741 shares of the company’s stock worth $276,000 after purchasing an additional 37,862 shares during the last quarter. UBS Group AG boosted its holdings in Tyme Technologies by 49.1% in the fourth quarter. UBS Group AG now owns 90,630 shares of the company’s stock worth $127,000 after purchasing an additional 29,829 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Tyme Technologies by 31.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 42,232 shares of the company’s stock worth $59,000 after purchasing an additional 10,124 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Tyme Technologies by 5.2% in the first quarter. Geode Capital Management LLC now owns 781,500 shares of the company’s stock worth $859,000 after purchasing an additional 38,310 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new stake in Tyme Technologies in the first quarter worth approximately $60,000. Institutional investors own 11.89% of the company’s stock.
A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $9.50 target price on shares of Tyme Technologies in a research note on Thursday, May 21st. Canaccord Genuity reaffirmed a “buy” rating on shares of Tyme Technologies in a research note on Monday, June 29th. Finally, Zacks Investment Research raised shares of Tyme Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, July 21st.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Recommended Story: Circuit Breakers
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.